Boundless Bio Q1 2026 net loss narrows to $13.6 million from $15.8 million
Boundless Bio reported first-quarter 2026 results with a net loss of $13.6 million, down from $15.8 million a year earlier, as research and development and general and administrative expenses both fell. The company reported no revenue in the filing, and cash, cash equivalents and short-term investments declined to $92.8 million from $107.6 million at December 31, 2025, which it says will fund operations into the second half of 2028.
Key points
- Net loss was $13.6 million for Q1 2026 versus $15.8 million for Q1 2025; net loss per share was $0.60 versus $0.71.
- R&D expenses were $9.7 million versus $12.1 million a year earlier; G&A expenses were $4.7 million versus $5.2 million.
- Cash and short-term investments were $92.8 million at March 31, 2026, down from $107.6 million at December 31, 2025.
- The company expects cash to fund operations into the second half of 2028, with initial KOMODO-1 clinical proof-of-concept data expected within that runway.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.